About
David W. Shen is the Founder and CEO of Propeller Bio, a role he began in February 2025. He previously founded and led Proteologix, which developed bispecific antibody therapeutics for immunology and inflammation and was acquired by Johnson & Johnson for $850 million in 2024, and held executive positions at NGM Biopharmaceuticals, Teva Pharmaceuticals, Merck, and Amgen, contributing to the development of antibody drug candidates including evolocumab, romosozumab, and denosumab. He holds 20 patents or applications and has authored more than 20 peer-reviewed publications.
Founder at Propeller
Intro paths
→
In turn, David can intro founders to Propeller's investors below.
Propeller's investors · 1
Experience
- Propeller BioFounder and CEOcurrent2025 — presentCalifornia, United States
- PROTEOLOGIX IncFounder and CEO2021 — 2024United States
- Elpiscience Biopharmaceuticals, Lilly Asia Venture backed comapnyBoard Member and Chairman of Scientific Advisory Board2017 — 2022Shanghai/San Francisco
- NGM BiopharmaceuticalsSenior Vice President, Head of Biologics Research, Bioanalyticals, and CMC2013 — 2021South San Francisco
- Teva PharmaceuticalsGlobal VP, Global Head of Biologics Development2010 — 2013
- Teva-Lonza BiopharmarceuticalsBoard member, Managing Director, Head of Joint Venture2010 — 2013
- Merck & Co. USAExecutive Director, Head of Biologics Research and GlycoFi, Merck Research Laboratory2008 — 2010
- AmgenDirector of Protein Sciences, Head of Amgen SF site1995 — 2008
- Whitehead InstitutePostdoctor Associate, MIT1991 — 1995
Skills & more
Biologics48Monoclonal Antibodies34Therapeutic Proteins9Optimization7Engineering5Drug Discovery99Protein Chemistry92Biotechnology99Antibodies10Neuroscience4Oncology41Biochemistry21
+10 more
CellAssay DevelopmentPharmaceutical IndustryTechnology TransferBiomarkersMolecular BiologyClinical ResearchClinical TrialsGMPTherapistsLanguages Chinese · English
From David's professional profile.
Frequently asked questions
- Who is David W. Shen?
- David W. Shen is the Founder and CEO of Propeller Bio, a role he began in February 2025. He previously founded and led Proteologix, which developed bispecific antibody therapeutics for immunology and inflammation and was acquired by Johnson & Johnson for $850 million in 2024, and held executive positions at NGM Biopharmaceuticals, Teva Pharmaceuticals, Merck, and Amgen, contributing to the development of antibody drug candidates including evolocumab, romosozumab, and denosumab. He holds 20 patents or applications and has authored more than 20 peer-reviewed publications.
- Where does David W. Shen work?
- David W. Shen is Founder of Propeller.
- What companies did David W. Shen found?
- David W. Shen founded Propeller.
- Where did David W. Shen go to school?
- David W. Shen studied at University of Toronto (Doctor of Philosophy (Ph.D.), Biochemistry); East China University of Science and Technology (B.Sc, Biochemistry).
Founder mafias
University of Toronto mafia155
Also came through, then founded or led a company.
Ilya SutskeverBachelor's degreeFounded Safe Superintelligence +1Nick FrosstBachelor's of ScienceFounded CohereJeffrey KarpPhDFounded Tissium +3Shvet JainMAScFounded Panther +1Som SeifBa.ScFounded Wealthsimple +1Peter SumaHBSc - Honours Bachelor of Science majoring inFounded Applied Brain Research +1
+ 148 more
East China University of Science and Technology mafia2
Also came through, then founded or led a company.
Same school
Also attended University of Toronto523
Ilya SutskeverCo-founder of OpenAI; co-founder & CEO of Safe SuperintelligenceNick FrosstCo-founder of CohereYasmin RazaviInvestor at Spark CapitalImran BashirFounding Partner, Chief Operating Officer at Extreme Venture PartnersKarim GillaniGeneral Partner at Luge CapitalAndrew MiklasGeneral Partner at Y Combinator
+ 517 more
Also attended East China University of Science and Technology4
Shared employers
Also worked at NGM Biopharmaceuticals4
Also worked at Teva Pharmaceuticals32
Catherine Pearce, DHSc, MBAAdvisor at CincyTechElad BaronInvestment Professional at Key1 CapitalElaine ShannonPresident, Global Supply & Quality at Takeda VenturesRiki MozesVice President, Chief People Officer at Jerusalem Venture Partners (JVP)Jill DeSimoneDigital Pharma Advisor at Excelerate Health VenturesPerry NisenExecutive Advisor, Private Equity at Sofinnova Ventures
+ 26 more
Also worked at Amgen87
Parker ConradCo-founder & CEO of RipplingSeth LieblichInvestment Team at 8VCSean BruichChief Technology Officer at Flare Capital PartnersSteph ScottVice President at Questa CapitalBeth SeidenbergFounding Managing Director at Westlake Village BioPartnersKelli McKeirnanDirector of Administration at Westlake Village BioPartners
+ 81 more
Also worked at Whitehead Institute12
Satish JindalGeneral Partner at Advent Life SciencesStella PaffenholzSenior Associate at Atlas VentureBetsy MuléPrincipal at F-Prime Capital PartnersBeccaInvestor at Sanofi VenturesJakob LovenPartner at Nextech InvestMichael LamprechtInvestment Manager at Tenmile
+ 6 more